Fleet Phospho-soda and the Food and Drug Administration

December 11, 2008, Food and Drug Administration Safety Alert:

"Oral Sodium Phosphate (OSP) Products for Bowel Cleansing"

"[I]n light of the risk of acute phosphate nephropathy, over-the-counter laxative OSP [oral sodium phosphate] products should not be used for bowel cleansing."

Click here for the complete text of the 2008 FDA Safety Alert.

May 5, 2006,  Food and Drug Administration Science Background Paper:

"Acute Phosphate Nephropathy and Renal Failure Associated With the Use of Oral Sodium Phosphate Bowel Cleansing Products"

“Healthcare professionals should be aware that acute phosphate nephropathy, a type of acute renal failure, is a rare, but serious adverse event associated with the use of oral sodium phosphate (OSP) products for bowel cleansing.”

Click here for the complete text of the 2006 paper.

September 17, 2001, Food and Drug Administration Science Backgrounder:

"Safety of Sodium Phosphates Oral Solution"

“Serious electrolyte disturbances (hypernatremia, hypokalemia, hyperphosphatemia, hypocalcemia) dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to physicians prescribing more than the 45 ml dose (usually a minimum of 90 ml during a 24-hour period) as a bowel preparation for colonoscopy, surgery, or barium enema and/or prescribing it for people at medical risk.”

“A published survey of Canadian colonoscopists, demonstrates that physicians who routinely prescribe bowel preparations are not adequately informed as to the medical risks and contraindications associated with the use of sodium phosphates oral solution.”

We may be able to help you get the compensation you deserve

The Fleet Phospho-soda lawsuit lawyers at Lynch Daskal Emery LLP have been representing individuals who suffered kidney damage after using Fleet Phospho-soda since 2004. Call Attorney Bernard Daskal to set up a free legal consultation.